Braveheart Bio, Inc.

BRVE

NASDAQHealthcareBiotechnology

GoAI で開く

終値時点

$27.45

+$0.74 · +2.77%

9月16日 16:00 ET

企業プロフィール

会社ウェブサイト

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

業界: Biotechnology
セクター: Healthcare
本社: US
最高経営責任者（CEO）: Travis Murdoch
上場以来: 2026年8月6日
従業員: 49

市場での位置

日中レンジ

現在 $27.45

$26.22$28.90

52週レンジ

現在 $27.45

$24.31$32.00

始値: $26.82
前日終値: $26.71
出来高: 55.07万; 1.25× 平均
平均出来高: 44.06万; 1日平均出来高
時価総額: 19.39億 USD
ベータ: 0; 市場参照 1
50日平均: $27.3482; 平均以上（+0.37%）
200日平均: $27.3482; 平均以上（+0.37%）

アナリスト評価

第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。

アナリストの目標株価

平均目標

$45.25

上昇余地（64.85%）

過去 12 か月12か月の予測最高：$48.00平均：$45.25最低：$40.00

BRVE ニュース

globenewswire.com2026年9月16日

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

ソースを読む

globenewswire.com2026年9月8日

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart…

ソースを読む

globenewswire.com2026年9月1日

Braveheart Bio to Participate in Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

ソースを読む

fool.com2026年8月10日

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?

The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.

ソースを読む

fool.com2026年8月10日

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?

The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this acquisition.

ソースを読む

fool.com2026年8月10日

Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?

Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.

ソースを読む